سعر امريستاتين 80مجم 10 أقراص 2022

Simvastatin 80 mg film-coated tablets (Amristatin, Amriya, Egypt), a statin; 10 tablets per pack. The 80 mg dose carries a higher myopathy risk and is restricted in the US reference label.

• To reduce the risk of total mortality (by reducing CHD death), non-fatal MI and stroke, and need for revascularisation in adults with established CHD, other atherosclerotic vascular disease or diabetes at high risk of coronary events (with diet).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet to reduce LDL-C in adults with primary hyperlipidaemia and in children/adolescents >=10 years with heterozygous familial hypercholesterolaemia; with other LDL-lowering therapy in homozygous FH.Population: Adults; paediatric >=10 years (HeFH)DailyMed (U.S. National Library of Medicine)
• Primary dysbetalipoproteinaemia and hypertriglyceridaemia in adults (adjunct to diet).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>=5%): upper respiratory infection (9%), headache (7%), abdominal pain (7%), constipation (7%) and nausea (5%).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Concomitant strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, posaconazole, voriconazole, HIV/HCV protease inhibitors, clarithromycin, erythromycin, telithromycin, nefazodone, cobicistat-containing products).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Concomitant cyclosporine, danazol or gemfibrozil.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Acute liver failure or decompensated cirrhosis; hypersensitivity to simvastatin or any excipient.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Restricted high dose: because of an increased risk of myopathy including rhabdomyolysis (particularly in the first year), the US label restricts simvastatin 80 mg daily to patients who have been taking 80 mg chronically (e.g. >=12 months) without evidence of muscle toxicity; patients unable to reach LDL-C goals on 40 mg should be switched to alternative LDL-lowering treatment rather than titrated to 80 mg.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Myopathy and rhabdomyolysis: risk increases with dose (myopathy about 0.61% with 80 mg in trials), age >=65, uncontrolled hypothyroidism, renal impairment and interacting drugs; advise patients to report unexplained muscle pain, tenderness or weakness; discontinue if CK is markedly elevated or myopathy is diagnosed.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotising myopathy (autoimmune) has been reported rarely with statins.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Verapamil, diltiazem, dronedaroneDo not exceed simvastatin 10 mg daily (increased myopathy risk).DailyMed (U.S. National Library of Medicine)
• Amiodarone, amlodipine, ranolazineDo not exceed simvastatin 20 mg daily.DailyMed (U.S. National Library of Medicine)
• LomitapideReduce simvastatin dose by 50%; do not exceed 20 mg daily (or 40 mg in patients already on 80 mg chronically).DailyMed (U.S. National Library of Medicine)

• Discontinue simvastatin when pregnancy is recognised (or consider the patient's ongoing therapeutic needs); it may cause fetal harm based on its mechanism, as it decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended during treatment with simvastatin.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Simvastatin: Prodrug hydrolysed to simvastatin acid, which inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor (US Zocor label).